Ankur Gupta1, Emily Lau1, Ravi Varshney1, Edward A Hulten2, Michael Cheezum3, Marcio S Bittencourt4, Michael J Blaha5, Nathan D Wong6, Roger S Blumenthal5, Matthew J Budoff7, Craig A Umscheid8, Khurram Nasir9, Ron Blankstein10. 1. Cardiovascular Imaging Program, Division of Cardiovascular Medicine and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Cardiovascular Imaging Program, Division of Cardiovascular Medicine and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Walter Reed National Military Medical Center, Washington, DC. 3. Cardiovascular Imaging Program, Division of Cardiovascular Medicine and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Fort Belvoir Community Hospital, Fort Belvoir, Virginia. 4. Cardiovascular Imaging Program, Division of Cardiovascular Medicine and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Center for Clinical and Epidemiological Research, University Hospital, University of Sao Paulo, Sao Paulo, Brazil; Hospital Israelita Albert Einstein and Faculdade Israelita de Ciencias da Saude Albert Einstein, Sao Paulo, Brazil. 5. John Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland. 6. University of California, Irvine, Irvine, California. 7. Harbor-University of California at Los Angeles, Torrance, California. 8. Penn Medicine, Philadelphia, Pennsylvania. 9. John Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland; Baptist Health South Florida, Miami, Florida. 10. Cardiovascular Imaging Program, Division of Cardiovascular Medicine and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: rblankstein@bwh.harvard.edu.
Abstract
OBJECTIVES: The aim of this study was to assess the odds of initiation or continuation of pharmacological and lifestyle preventive therapies in patients with nonzero versus zero coronary artery calcium (CAC) score detected on cardiac computed tomography. BACKGROUND: Detection of calcified coronary plaque could serve as a motivational tool for physicians and patients to intensify preventive therapies. METHODS: We searched PubMed, EMBASE (Excerpta Medica database), Web of Science, Cochrane CENTRAL (Cochrane central register of controlled trials), ClinicalTrials.gov, and the International Clinical Trials Registry Platform for studies evaluating the association of CAC scores with downstream pharmacological or lifestyle interventions for prevention of cardiovascular disease. Pooled odds ratios (ORs) of downstream interventions were obtained using the DerSimonian and Laird random effects model. RESULTS: After a review of 6,256 citations and 54 full-text papers, 6 studies (11,256 participants, mean follow-up time: 1.6 to 6.0 years) were included. Pooled estimates of the odds of aspirin initiation (OR: 2.6; 95% confidence interval [CI]: 1.8 to 3.8), lipid-lowering medication initiation (OR: 2.9; 95% CI: 1.9 to 4.4), blood pressure-lowering medication initiation (OR: 1.9; 95% CI: 1.6 to 2.3), lipid-lowering medication continuation (OR: 2.3; 95% CI: 1.6 to 3.3), increase in exercise (OR: 1.8; 95% CI: 1.4 to 2.4), and dietary change (OR: 1.9; 95% CI: 1.5 to 2.5) were higher in individuals with nonzero CAC versus zero CAC scores, but not for aspirin or blood pressure-lowering medication continuation. When assessed within individual studies, these findings remained significant after adjustment for baseline patient characteristics and cardiovascular risk factors. CONCLUSIONS: This systematic review and meta-analysis suggests that nonzero CAC score, identifying calcified coronary plaque, significantly increases the likelihood of initiation or continuation of pharmacological and lifestyle therapies for the prevention of cardiovascular disease.
OBJECTIVES: The aim of this study was to assess the odds of initiation or continuation of pharmacological and lifestyle preventive therapies in patients with nonzero versus zero coronary artery calcium (CAC) score detected on cardiac computed tomography. BACKGROUND: Detection of calcified coronary plaque could serve as a motivational tool for physicians and patients to intensify preventive therapies. METHODS: We searched PubMed, EMBASE (Excerpta Medica database), Web of Science, Cochrane CENTRAL (Cochrane central register of controlled trials), ClinicalTrials.gov, and the International Clinical Trials Registry Platform for studies evaluating the association of CAC scores with downstream pharmacological or lifestyle interventions for prevention of cardiovascular disease. Pooled odds ratios (ORs) of downstream interventions were obtained using the DerSimonian and Laird random effects model. RESULTS: After a review of 6,256 citations and 54 full-text papers, 6 studies (11,256 participants, mean follow-up time: 1.6 to 6.0 years) were included. Pooled estimates of the odds of aspirininitiation (OR: 2.6; 95% confidence interval [CI]: 1.8 to 3.8), lipid-lowering medication initiation (OR: 2.9; 95% CI: 1.9 to 4.4), blood pressure-lowering medication initiation (OR: 1.9; 95% CI: 1.6 to 2.3), lipid-lowering medication continuation (OR: 2.3; 95% CI: 1.6 to 3.3), increase in exercise (OR: 1.8; 95% CI: 1.4 to 2.4), and dietary change (OR: 1.9; 95% CI: 1.5 to 2.5) were higher in individuals with nonzero CAC versus zero CAC scores, but not for aspirin or blood pressure-lowering medication continuation. When assessed within individual studies, these findings remained significant after adjustment for baseline patient characteristics and cardiovascular risk factors. CONCLUSIONS: This systematic review and meta-analysis suggests that nonzero CAC score, identifying calcified coronary plaque, significantly increases the likelihood of initiation or continuation of pharmacological and lifestyle therapies for the prevention of cardiovascular disease.
Authors: Seamus P Whelton; Khurram Nasir; Michael J Blaha; Heidi Gransar; Thomas S Metkus; Josef Coresh; Daniel S Berman; Roger S Blumenthal Journal: Circ Cardiovasc Qual Outcomes Date: 2012-07-01
Authors: Joseph B Muhlestein; Donald L Lappé; Joao A C Lima; Boaz D Rosen; Heidi T May; Stacey Knight; David A Bluemke; Steven R Towner; Viet Le; Tami L Bair; Andrea L Vavere; Jeffrey L Anderson Journal: JAMA Date: 2014-12-03 Impact factor: 56.272
Authors: N D Wong; R C Detrano; G Diamond; C Rezayat; R Mahmoudi; E C Chong; W Tang; G Puentes; X Kang; D Abrahamson Journal: Am J Cardiol Date: 1996-12-01 Impact factor: 2.778
Authors: Khurram Nasir; Robyn L McClelland; Roger S Blumenthal; David C Goff; Udo Hoffmann; Bruce M Psaty; Philip Greenland; Richard A Kronmal; Matthew J Budoff Journal: Circ Cardiovasc Qual Outcomes Date: 2010-04-06
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Nove K Kalia; Loren G Miller; Khurram Nasir; Roger S Blumenthal; Nisha Agrawal; Matthew J Budoff Journal: Atherosclerosis Date: 2005-07-26 Impact factor: 5.162
Authors: Khurram Nasir; Marcio S Bittencourt; Michael J Blaha; Ron Blankstein; Arthur S Agatson; Juan J Rivera; Michael D Miedema; Michael D Miemdema; Christopher T Sibley; Leslee J Shaw; Roger S Blumenthal; Matthew J Budoff; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2015-10-13 Impact factor: 24.094
Authors: Parag H Joshi; Birju Patel; Michael J Blaha; Jarett D Berry; Ron Blankstein; Matthew J Budoff; Nathan Wong; Arthur Agatston; Roger S Blumenthal; Khurram Nasir Journal: Atherosclerosis Date: 2016-01-13 Impact factor: 5.162
Authors: Miguel Cainzos-Achirica; Philip A Di Carlo; Catherine E Handy; Renato Quispe; Gerard Roura; Xavier Pinto; Roger S Blumenthal; Josep Comin-Colet; Xavier Corbella; Michael J Blaha Journal: Curr Cardiol Rep Date: 2018-07-10 Impact factor: 2.931
Authors: Dalton Bertolim Précoma; Gláucia Maria Moraes de Oliveira; Antonio Felipe Simão; Oscar Pereira Dutra; Otávio Rizzi Coelho; Maria Cristina de Oliveira Izar; Rui Manuel Dos Santos Póvoa; Isabela de Carlos Back Giuliano; Aristóteles Comte de Alencar Filho; Carlos Alberto Machado; Carlos Scherr; Francisco Antonio Helfenstein Fonseca; Raul Dias Dos Santos Filho; Tales de Carvalho; Álvaro Avezum; Roberto Esporcatte; Bruno Ramos Nascimento; David de Pádua Brasil; Gabriel Porto Soares; Paolo Blanco Villela; Roberto Muniz Ferreira; Wolney de Andrade Martins; Andrei C Sposito; Bruno Halpern; José Francisco Kerr Saraiva; Luiz Sergio Fernandes Carvalho; Marcos Antônio Tambascia; Otávio Rizzi Coelho-Filho; Adriana Bertolami; Harry Correa Filho; Hermes Toros Xavier; José Rocha Faria-Neto; Marcelo Chiara Bertolami; Viviane Zorzanelli Rocha Giraldez; Andrea Araújo Brandão; Audes Diógenes de Magalhães Feitosa; Celso Amodeo; Dilma do Socorro Moraes de Souza; Eduardo Costa Duarte Barbosa; Marcus Vinícius Bolívar Malachias; Weimar Kunz Sebba Barroso de Souza; Fernando Augusto Alves da Costa; Ivan Romero Rivera; Lucia Campos Pellanda; Maria Alayde Mendonça da Silva; Aloyzio Cechella Achutti; André Ribeiro Langowiski; Carla Janice Baister Lantieri; Jaqueline Ribeiro Scholz; Silvia Maria Cury Ismael; José Carlos Aidar Ayoub; Luiz César Nazário Scala; Mario Fritsch Neves; Paulo Cesar Brandão Veiga Jardim; Sandra Cristina Pereira Costa Fuchs; Thiago de Souza Veiga Jardim; Emilio Hideyuki Moriguchi; Jamil Cherem Schneider; Marcelo Heitor Vieira Assad; Sergio Emanuel Kaiser; Ana Maria Lottenberg; Carlos Daniel Magnoni; Marcio Hiroshi Miname; Roberta Soares Lara; Artur Haddad Herdy; Cláudio Gil Soares de Araújo; Mauricio Milani; Miguel Morita Fernandes da Silva; Ricardo Stein; Fernando Antonio Lucchese; Fernando Nobre; Hermilo Borba Griz; Lucélia Batista Neves Cunha Magalhães; Mario Henrique Elesbão de Borba; Mauro Ricardo Nunes Pontes; Ricardo Mourilhe-Rocha Journal: Arq Bras Cardiol Date: 2019-11-04 Impact factor: 2.000
Authors: Philip Greenland; Michael J Blaha; Matthew J Budoff; Raimund Erbel; Karol E Watson Journal: J Am Coll Cardiol Date: 2018-07-24 Impact factor: 24.094
Authors: Michael C Honigberg; Bradley S Lander; Vinit Baliyan; Maeve Jones-O'Connor; Emma W Healy; Jan-Erik Scholtz; John T Nagurney; Udo Hoffmann; Brian B Ghoshhajra; Pradeep Natarajan Journal: JACC Cardiovasc Imaging Date: 2019-07-17
Authors: Anna Fretz; John W McEvoy; Casey M Rebholz; Chiadi E Ndumele; Roberta Florido; Ron C Hoogeveen; Christie M Ballantyne; Elizabeth Selvin Journal: Am J Cardiol Date: 2017-11-24 Impact factor: 2.778